Global STD Diagnostics Market Size By Type (Chlamydia Testing, Gonorrhea Testing), By Location of Test (Laboratory Tests, Point of Care Tests), By Devices Type (Thermal Cyclers - PCR, Point Of Care (PoC) Devices), By End-User (Diagnostics Centers, Government Organizations), By Geography Scope And Forecast

Report ID: 329170|No. of Pages: 202

product image

Global STD Diagnostics Market Size By Type (Chlamydia Testing, Gonorrhea Testing), By Location of Test (Laboratory Tests, Point of Care Tests), By Devices Type (Thermal Cyclers - PCR, Point Of Care (PoC) Devices), By End-User (Diagnostics Centers, Government Organizations), By Geography Scope And Forecast

Report ID: 329170|Published Date: Sep 2024|No. of Pages: 202|Base Year for Estimate: 2024|Format:   Report available in PDF formatReport available in Excel Format

STD Diagnostics Market Size And Forecast

STD Diagnostics Market size was valued at USD 107.2 Billion in 2024 and is projected to reach USD 190.7 Billion by 2031, growing at a CAGR of 7.46% from 2024 to 2031. 

The rising prevalence of STDs is the primary driver of the worldwide STD testing industry. The Global STD Diagnostics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

STD Diagnostics Market is estimated to grow at a CAGR of 7.46% & reach US$ 190.7 Bn by the end of 2031

Global STD Diagnostics Market Executive Summary

A Sexually Transmitted Diseases (STDs) are sexually transmitted infections that are often contracted through intercourse, blood transfusions, the use of unsterilized medication needles, and mother-to-child transmission during delivery or breastfeeding. These diseases don’t have any symptoms and are identified by a variety of tests, such as blood, urine, or fluid samples. It can be done to cure STDs caused on by bacteria with the use of antibiotics and antiviral medications. Some of the instruments used to diagnose the disease include immunochromatographic tests, flow cytometers, and absorbance microplate readers and others.

The standards that society maintains for sexual behavior have changed significantly throughout time. The danger of spreading STDs has increased as a result of this alteration in sexual behavior, prompting more efforts in diagnosis. Also, the prevalence of STDs may be attributed to limited or inadequate sex education programs. There is an increased probability of transmission when people lack the information and abilities necessary to participate in safe sexual behavior.

The emergence of antibiotic-resistant strains of bacteria that because STDs is a growing concern. This necessitates more vigilant and widespread diagnostic efforts to promptly administer appropriate treatments. The expansion of diagnosis is crucial for monitoring the prevalence of antibiotic-resistant strains and adapting treatment strategies accordingly. In addition, Technological developments in medicine have entirely transformed the diagnosis of STDs. Infection detection has become more straightforward with quicker and more precise diagnostic instruments, such as point-of-care and nucleic acid amplification tests (NAATs). These instruments’ efficiency and accessibility have a significant impact on the growth of STD diagnosis by rendering infections easier to identify and treat for medical practitioners.

What's inside a VMR
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

vmr

>>> Ask For Discount @ – https://www.verifiedmarketresearch.com/ask-for-discount/?rid=329170

Global STD Diagnostics Market Attractiveness Analysis

The Global Sexually Transmitted Disease (STD) Diagnosis market is experiencing a scaled level of attractiveness in the North America region. The North America region has a prominent presence and holds the major share of the global market.   North America is anticipated to account for the significant market share of 36.92% by 2030.

North America dominates the global market for the diagnosis of STDs. The US is expected to be the largest market in the North American region because of the vast number of diagnostic firms and the rising awareness of illnesses. 41,655 of the 133,945 cases of syphilis that were recorded in 2020 were in the primary and secondary (P&S) phases of the illness, which are the most transmittable. Due to the increased demand for diagnostic procedures relevant to these conditions, the country’s market is anticipated to grow as STD incidence rises.

Geographical Representation of STD Diagnostics Market

Global STD Diagnostics Market Outlook

The rising prevalence of STDs is the primary driver of the worldwide STD testing industry. STDs are caused by the transmission of various bacteria, viruses, and parasites through vaginal fluid exchange. Both men and women can be affected by STDs. Syphilis, gonorrhoea, chlamydia, hepatitis B, genital herpes, and HIV/AIDS are examples of STDs. HPV and Trichomoniasis vaginalis can also cause STDs. Syphilis, gonorrhoea, chlamydia, and trichomoniasis are treatable, but hepatitis B, genital herpes, HIV/AIDS, and HPV-related STDs are not. There have been continual innovations in the field of molecular diagnostics, which is one of the primary causes responsible for the expansion of STD diagnosis.

More product introductions are allowing laboratories to install instruments or equipment as needed. For example, Qiagen Inc. received European Commission clearance in May 2022 to produce Neu-MoDxHSV 1/2 Quant Assay for the measurement and distinction of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2). The lack of healthcare services in developing countries is a major hindrance to the global STD testing market’s progress. A significant section of the population in growing nations such as Asia, the Middle East, and North Africa lacks adequate health information and access to proper healthcare services. This propensity is exacerbated by a lack of financial and human resources for medical treatment, which is a significant hindrance to public health promotion and adds to a large HIV-infected population.

Proactive healthcare is being promoted by increased awareness of the significance of rou-tine STD evaluations. According to estimates from the World Health Organisation (WHO), over 311,000 cervical cancer deaths occur yearly as a consequence of human papillomavirus (HPV) infection. Healthcare authorities, governments, and non-profit organizations have prioritized STD prevention and control due to the increasing burden. This has led to an ideal environment for the expansion of the STD diagnosis industry. For instance, the National Health Service (NHS) in the United Kingdom and the Centres for Disease Control and Pre-vention (CDC) in the United States have placed extensive programs to inform the public and promote routine STD screening.

Global STD Diagnostics Market Segmentation Analysis

The Global STD Diagnostics Market is segmented on the basis of Type, Location of Test, Devices Type, End-User, and Geography.

STD Diagnostics Market Segmentation Analysis

STD Diagnostics Market, By Type

  • Chlamydia Testing
  • Gonorrhoea Testing
  • Syphilis Testing
  • Human Papillomavirus (HPV) Testing
  • Human Immunodeficiency Viruses (HIV) Testing
  • Herpes Simplex Virus (HSV) Testing
  • Human papillomavirus (HPV)
  • Trichomonas Vaginalis (TV) Testing

STD Diagnostics Market By Type

To Get a Summarized Market Report By Type:- Download the Sample Report Now

Based on Type, the market is segmented into Chlamydia Testing, Gonorrhea Testing, Syphilis Testing, Human Papillomavirus (HPV) Testing, Human Immunodeficiency Viruses (HIV) Testing, Herpes Simplex Virus (HSV) Testing, and Trichomonas Vaginalis (TV) Testing. Chlamydia Testing accounted for the largest market share of 31.37% in 2022 and is projected to grow at a CAGR of 5.69% during the forecast period. The bacteria that cause chlamydia, a sexually transmitted illness (STI), are identified using a chlamydia test. It is frequently asymptomatic and can infect both men and women. Nucleic acid amplification tests are a standard method to test for chlamydia (NAATs). Molecular tests known as NAATs are compassionate and specific tools for identifying the genetic material of the Chlamydia trachomatis bacteria. Urine, vaginal, penile, and rectal swabs are among the samples that can be used for these testing. Because urine samples are non-invasive, NAATs are especially useful for screening. Routine STI screening programs frequently include chlamydia testing, particularly for those who are more at risk, such as young adults who are sexually active, pregnant women, and those who have many sexual partners.

STD Diagnostics Market, By Location of Test

  • Laboratory Tests
  • Point of Care Tests

Based on Location of Test, the market is segmented into Laboratory Tests and Point of Care Tests. Laboratory Tests accounted for the largest market share of 76.26% in 2022 and is projected to grow at a CAGR of 7.19% during the forecast period. The diagnosis and treatment of sexually transmitted diseases (STDs) depend significantly on laboratory testing. Different laboratory procedures are utilized to diagnose sexually transmitted diseases (STDs); each has a unique application for accuracy, specificity, and productivity. Flow Cytometry analyses several biological indicators simultaneously, which helps discover co-infections. Applying flow cytometry for research to comprehend the immunology of sexually transmitted diseases is beneficial. Moreover, several pathogens can be detected by PCR in a single test, offering a thorough evaluation of the infection state.

STD Diagnostics Market, By Devices Type

  • Thermal Cyclers – PCR
  • Lateral Flow Readers Immunochromatographic Assays
  • Flow Cytometers
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Point Of Care (PoC) Devices
  • Phone Chips (Microfluidics + ICT)
  • Porta-ble/Bench Top/Rapid Diagnostic Kits
  • Others

Based on Devices Type, the market is segmented into Thermal Cyclers – PCR, Lateral Flow Readers Immunochromatographic Assays, Flow Cytometers, Enzyme Linked Immunosorbent Assay (ELISA), Point Of Care (PoC) Devices, Phone Chips (Microfluidics + ICT), Porta-ble/Bench Top/Rapid Diagnostic Kits, Others. Thermal Cyclers – PCR accounted for the largest market share of 43.98% in 2022 and is projected to grow at a CAGR of 6.78% during the forecast period. Thermal cyclers are sometimes called PCR (Polymerase Chain Reaction) equipment. The process of PCR is employed to diagnose sexually transmitted diseases (STDs) by amplifying DNA or RNA from pathogens, such as bacteria or viruses. The three primary phases of PCR—denaturation, annealing, and extension—require temperature cycling, which is accomplished significantly with thermal cyclers. Because PCR is so accurate, it may identify infections in miserable quantities, which is essential for early STD diagnosis. This sensitivity is especially crucial when treating STDs since the virus may initially present in low proportions.

STD Diagnostics Market, By End-User

  • Hospitals & Clinics
  • Diagnostics Centers
  • Government Organizations

Based on End-User, the market is segmented into Hospitals & Clinics, Diagnostics Centers, and Government Organizations. Hospitals & Clinics accounted for the largest market share of 55.77% in 2022 and are projected to grow at a CAGR of 7.12% during the forecast period. Hospitals and clinics provide STD-related counseling and educational services alongside the diagnosis. Healthcare providers offer advice on safe procedures, infection prevention, and the possible implications of leaving infections undiagnosed. Counseling sessions provide a supportive atmosphere for patients to manage the problems associated with sexually transmitted illnesses by addressing the emotional and psychological components of living with an STD.

STD Diagnostics Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

STD Diagnostics Market By Geography

To Get a Summarized Market Report By Geography:- Download the Sample Report Now

On the basis of Geography, The Global STD Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest market share of 38.27% in 2022 and is projected to grow at a CAGR of 6.93% during the forecast period. Due to the high prevalence of STDs in the region, North America leads the world market for the diagnosis of sexually transmitted illnesses. Because of the high number of diagnostic firms and increased awareness of diseases, the United States is anticipated to be the largest market in the North American area. The Centers for Disease Control and Prevention (CDC) released a report in April 2022 titled “Sexually Transmitted Disease Surveillance, 2020” which indicated that STDs continue to be a major public health concern in the nation.

Europe was the second-largest market in 2022, and it is projected to grow at a CAGR of 7.25%. The increased public awareness and patient education are driving the growth of the sexually transmitted diseases (STD) diagnostics market. Furthermore, an increase in the number of education programs and government initiatives would fuel the demand for STD diagnostics. STD prevalence and incidence have skyrocketed in the last decade. Several countries around the world are focusing heavily on implementing nationwide screening programs to increase STD diagnosis coverage. Furthermore, reimbursement policies for STD services have benefited patients, which is contributing significantly to the growth of the STD testing market.

Key Players

The “Global STD Diagnostics Market” study report will provide valuable insight emphasizing the global market. The major players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, BIOMÉRIEUX, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., QuidelOrtho Corporation, Hologic, Inc., OraSure Technologies, Siemens, Illumina Inc., See-gene Inc., Qiagen, MedMira Inc., and Cepheid. This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

STD Diagnostics Market Key Developments And Mergers

  • In February 2022, Lupin Limited, a Mumbai-based Indian Pharmaceutical firm- received approval from the U.S. FDA for the use of its antibiotic Solosec for treating sexually transmitted infections referred to as trichomoniasis and vaginal infection termed as bacterial vaginosis in women.
  • In February 2022, Trinity Biotech, a Medical Laboratory Company based in Ireland & specializing in the production and marketing of clinically diagnostic products- has got the approval of the WHO for HIV screening tests.

Company Regional Footprint

The company’s regional section provides geographical presence, regional level reach, or the respective company’s sales network presence. For instance, F. Hoffmann-La Roche Ltd has its presence globally i.e. in North America, Europe, Asia Pacific and RoW. All the companies considered for profiling are reviewed similarly under this section. These sections help us to understand the overall STD Diagnostics Market presence on a global and country level.

Ace Matrix

This section of the report provides an overview of the company evaluation scenario in the STD Diagnostics Market. The company evaluation has been carried out based on the outcomes of the qualitative and quantitative analyses of various factors such as the product portfolios, technological innovations, market presence, revenues of companies, and the opinions of primary respondents.

Ace Matrix Analysis of STD Diagnostics Market

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in the global STD Diagnostics Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

Porter\'s Five Forces Framework of STD Diagnostics Market

Report Scope

REPORT ATTRIBUTESDETAILS
STUDY PERIOD

2021-2031

BASE YEAR

2024

FORECAST PERIOD

2024-2031

HISTORICAL PERIOD

2021-2023

UNIT

Value (USD Billion)

KEY COMPANIES PROFILED

Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, BIOMÉRIEUX, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., QuidelOrtho Corporation, Hologic, Inc., OraSure Technologies, Siemens, Illumina Inc., See-gene Inc., Qiagen, MedMira Inc., and Cepheid.

SEGMENTS COVERED

By Type, By Location of Test, By Devices Type, By End-User, and By Geography.

CUSTOMIZATION SCOPE

Free report customization (equivalent to up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

To Get Customized Report Scope:- Request For Customization Now

Top Trending Reports:

Global Packaged Cactus Water Market Size And Forecast

Global Breast Cancer Market Size And Forecast

Research Methodology of Verified Market Research:

Research Methodology of VMR

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research.

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.

Frequently Asked Questions

STD Diagnostics Market size was valued at USD 107.2 Billion in 2024 and is projected to reach USD 190.7 Billion by 2031, growing at a CAGR of 7.46% from 2024 to 2031. 

Increasing prevalence of STDs and growing innovations in the development of STD diagnostics are driving the STD Diagnostics in coming years.

The major players are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, BIOMÉRIEUX, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., QuidelOrtho Corporation, Hologic, Inc., OraSure Technologies, Siemens, Illumina Inc., See-gene Inc., Qiagen, MedMira Inc., and Cepheid.

The Global STD Diagnostics Market is segmented on the basis of Type, Location of Test, Devices Type, End-User, and Geography.

The sample report for the STD Diagnostics Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
1 INTRODUCTION 
1.1 MARKET DEFINITION
1.2 MARKET SEGMENTATION
1.3 RESEARCH TIMELINES
1.4 ASSUMPTIONS
1.5 LIMITATIONS
 
2 RESEARCH METHODOLOGY
2.1 DATA MINING
2.2 SECONDARY RESEARCH
2.3 PRIMARY RESEARCH
2.4 SUBJECT MATTER EXPERT ADVICE
2.5 QUALITY CHECK
2.6 FINAL REVIEW
2.7 DATA TRIANGULATION
2.8 BOTTOM-UP APPROACH
2.9 TOP-DOWN APPROACH
2.10 RESEARCH FLOW
2.11 DATA SOURCES
 
3 EXECUTIVE SUMMARY
3.1 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET OVERVIEW
3.2 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ESTIMATES AND FORECAST (USD MILLION), 2021-2030
3.3 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSISMARKET VALUE (USD MILLION) ESTIMATES AND FORECAST, 2024-2030
3.4 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS ECOLOGY MAPPING (% SHARE IN 2022)
3.5 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
3.6 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ABSOLUTE MARKET OPPORTUNITY
3.7 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY REGION
3.8 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY LOCATION OF TEST
3.9 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY DEVICES
3.10 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY TYPE
3.11 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY END USER
3.12 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
3.13 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST (USD MILLION)
3.14 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES (USD MILLION)
3.15 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE (USD MILLION)
3.16 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER (USD MILLION)
3.17 FUTURE MARKET OPPORTUNITIES
 
4 MARKET OUTLOOK
 
4.1 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET EVOLUTION
 
4.2 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET OUTLOOK
 
4.3 MARKET DRIVERS
4.3.1 INCREASING PREVALENCE OF STDS
4.3.2 GROWING INNOVATIONS IN THE DEVELOPMENT OF STD DIAGNOSTICS
 
4.4 MARKET RESTRAINTS
4.4.1 LIMITED HEALTHCARE SERVICES IN DEVELOPING REGIONS
4.4.1 RISE IN AWARENESS ABOUT SPREAD OF SEXUALLY TRANSMITTED DISEASES SUCH AS HIV
 
4.5 MARKET TRENDS
4.5.1 INCREASED AWARENESS AND SCREENING PROGRAMS
4.5.2 RISING DEMAND FOR POINT-OF-CARE TESTING
 
4.6 MARKET OPPORTUNITY
4.6.1 INCREASING SIGNIFICANCE FOR HOME TESTING KITS
4.6.2 DEVELOPMENTS IN TECHNOLOGY AND MOLECULAR DIAGNOSTICS
 
4.7 PORTER’S FIVE FORCES ANALYSIS
4.7.1 THREAT OF NEW ENTRANTS
4.7.2 THREAT OF SUBSTITUTES
4.7.3 BARGAINING POWER OF SUPPLIERS
4.7.4 BARGAINING POWER OF BUYERS
4.7.5 INTENSITY OF COMPETITIVE RIVALRY
 
4.8 MACROECONOMIC ANALYSIS
 
4.9 VALUE CHAIN ANALYSIS
 
4.10 PRICING ANALYSIS
 
4.11 REGULATIONS
4.11.1 USFDA
4.11.2 EUROPEAN UNION (EU)
 
5 MARKET, BY LOCATION OF TEST
5.1 OVERVIEW
5.2 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY LOCATION OF TEST
5.3 LABORATORY TESTS
5.4 POINT OF CARE TESTS
 
6 MARKET, BY DEVICES TYPE
6.1 OVERVIEW
6.2 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY DEVICES
6.3 THERMAL CYCLERS – PCR
6.4 LATERAL FLOW READERS IMMUNOCHROMATOGRAPHIC ASSAYS
6.5 FLOW CYTOMETERS
6.6 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
6.7 POINT OF CARE (POC) DEVICES
6.8 PHONE CHIPS (MICROFLUIDICS + ICT)
6.9 PORTABLE/BENCH TOP/RAPID DIAGNOSTIC KITS
6.10 OTHERS
 
7 MARKET, BY TYPE
7.1 OVERVIEW
7.2 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TYPE
7.3 CHLAMYDIA TESTING
7.4 GONORRHEA TESTING
7.5 SYPHILIS TESTING
7.6 HUMAN PAPILLOMAVIRUS (HPV) TESTING
7.7 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) TESTING
7.8 HERPES SIMPLEX VIRUS (HSV) TESTING
7.9 TRICHOMONAS VAGINALIS (TV) TESTING
 
8 MARKET, BY END-USER
8.1 OVERVIEW
8.2 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END USER
8.3 HOSPITALS & CLINICS
8.4 DIAGNOSTICS CENTERS
8.5 GOVERNMENT ORGANIZATIONS
 
9 MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 GERMANY
9.3.3 U.K.
9.3.4 FRANCE
9.3.5 ITALY
9.3.6 SPAIN
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 INDONESIA
9.4.6 PHILIPPINES
9.4.7 THAILAND
9.4.8 VIETNAM
9.4.9 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 LATIN AMERICA MARKET SNAPSHOT
9.5.2 BRAZIL
9.5.3 ARGENTINA
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST AND AFRICA
9.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
9.6.2 UAE
9.6.3 SAUDI ARABIA
9.6.4 SOUTH AFRICA
9.6.5 REST OF MIDDLE EAST AND AFRICA
 
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING ANALYSIS
10.3 COMPANY REGIONAL FOOTPRINT
10.4 COMPANY INDUSTRY FOOTPRINT
10.5 ACE MATRIX
10.5.1 ACTIVE
10.5.2 CUTTING EDGE
10.5.3 EMERGING
10.5.4 INNOVATORS
 
11 COMPANY PROFILES
 
11.1 F. HOFFMANN-LA ROCHE LTD
11.1.1 COMPANY OVERVIEW
11.1.2 COMPANY INSIGHTS
11.1.3 SEGMENT BREAKDOWN
11.1.4 PRODUCT BENCHMARKING
11.1.5 SWOT ANALYSIS
11.1.6 WINNING IMPERATIVES
11.1.7 CURRENT FOCUS & STRATEGIES
11.1.8 THREAT FROM COMPETITION
 
11.2 ABBOTT LABORATORIES
11.2.1 COMPANY OVERVIEW
11.2.2 COMPANY INSIGHTS
11.2.3 SEGMENT BREAKDOWN
11.2.4 PRODUCT BENCHMARKING
11.2.5 KEY DEVELOPMENTS
11.2.6 SWOT ANALYSIS
11.2.7 WINNING IMPERATIVES
11.2.8 CURRENT FOCUS & STRATEGIES
11.2.9 THREAT FROM COMPETITION
 
11.3 DANAHER
11.3.1 COMPANY OVERVIEW
11.3.2 COMPANY INSIGHTS
11.3.3 SEGMENT BREAKDOWN
11.3.4 PRODUCT BENCHMARKING
11.3.5 SWOT ANALYSIS
11.3.6 WINNING IMPERATIVES
11.3.7 CURRENT FOCUS & STRATEGIES
11.3.8 THREAT FROM COMPETITION
 
11.4 THERMO FISHER SCIENTIFIC, INC.
11.4.1 COMPANY OVERVIEW
11.4.2 COMPANY INSIGHTS
11.4.3 SEGMENT BREAKDOWN
11.4.4 PRODUCT BENCHMARKING
11.4.5 SWOT ANALYSIS
11.4.6 WINNING IMPERATIVES
11.4.7 CURRENT FOCUS & STRATEGIES
11.4.8 THREAT FROM COMPETITION
 
11.5 HOLOGIC, INC.
11.5.1 COMPANY OVERVIEW
11.5.2 COMPANY INSIGHTS
11.5.3 SEGMENT BREAKDOWN
11.5.4 PRODUCT BENCHMARKING
11.5.5 SWOT ANALYSIS
11.5.6 WINNING IMPERATIVES
11.5.7 CURRENT FOCUS & STRATEGIES
11.5.8 THREAT FROM COMPETITION
 
11.6 BIOMÉRIEUX
11.6.1 COMPANY OVERVIEW
11.6.2 COMPANY INSIGHTS
11.6.3 SEGMENT BREAKDOWN
11.6.4 PRODUCT BENCHMARKING
 
11.7 BECTON, DICKINSON AND COMPANY
11.7.1 COMPANY OVERVIEW
11.7.2 COMPANY INSIGHTS
11.7.3 SEGMENT BREAKDOWN
11.7.4 PRODUCT BENCHMARKING
 
11.8 BIO-RAD LABORATORIES, INC.
11.8.1 COMPANY OVERVIEW
11.8.2 COMPANY INSIGHTS
11.8.3 SEGMENT BREAKDOWN
11.8.4 PRODUCT BENCHMARKING
 
11.9 DIASORIN S.P.A.
11.9.1 COMPANY OVERVIEW
11.9.2 COMPANY INSIGHTS
11.9.3 SEGMENT BREAKDOWN
11.9.4 PRODUCT BENCHMARKING
 
11.10 QUIDELORTHO CORPORATION
11.10.1 COMPANY OVERVIEW
11.10.2 COMPANY INSIGHTS
11.10.3 SEGMENT BREAKDOWN
11.10.4 PRODUCT BENCHMARKING
 
11.11 ORASURE TECHNOLOGIES
11.11.1 COMPANY OVERVIEW
11.11.2 COMPANY INSIGHTS
11.11.3 SEGMENT BREAKDOWN
11.11.4 PRODUCT BENCHMARKING
 
11.12 SIEMENS
11.12.1 COMPANY OVERVIEW
11.12.2 COMPANY INSIGHTS
11.12.3 SEGMENT BREAKDOWN
11.12.4 PRODUCT BENCHMARKING
 
11.13 ILLUMINA, INC.
11.13.1 COMPANY OVERVIEW
11.13.2 COMPANY INSIGHTS
11.13.3 SEGMENT BREAKDOWN
11.13.4 PRODUCT BENCHMARKING
 
11.14 SEEGENE INC.
11.14.1 COMPANY OVERVIEW
11.14.2 COMPANY INSIGHTS
11.14.3 PRODUCT BENCHMARKING
 
11.15 QIAGEN’
11.15.1 COMPANY OVERVIEW
11.15.2 COMPANY INSIGHTS
11.15.3 SEGMENT BREAKDOWN
11.15.4 PRODUCT BENCHMARKING
 
11.16 MEDMIRA INC.
11.16.1 COMPANY OVERVIEW
11.16.2 COMPANY INSIGHTS
11.16.3 PRODUCT BENCHMARKING
 
11.17 CEPHEID
11.17.1 COMPANY OVERVIEW
11.17.2 COMPANY INSIGHTS
11.17.3 PRODUCT BENCHMARKING
 
LIST OF TABLES
TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
TABLE 2 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 12 U.S. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 13 U.S. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 14 U.S. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 U.S. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 16 CANADA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 17 CANADA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 18 CANADA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 CANADA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 20 MEXICO SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 21 MEXICO SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 22 MEXICO SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 23 MEXICO SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 24 EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 25 EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 26 EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 27 EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 28 EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 29 GERMANY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 30 GERMANY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 31 GERMANY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 32 GERMANY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 33 U.K. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 34 U.K. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 35 U.K. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 36 U.K. SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 FRANCE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 38 FRANCE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 39 FRANCE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 40 FRANCE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 ITALY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 42 ITALY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 43 ITALY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 44 ITALY SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 45 SPAIN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 46 SPAIN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 47 SPAIN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 SPAIN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 49 REST OF EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 50 REST OF EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 51 REST OF EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 REST OF EUROPE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 53 ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 54 ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 55 ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 56 ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 57 ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 58 CHINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 59 CHINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 60 CHINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 61 CHINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 62 JAPAN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 63 JAPAN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 64 JAPAN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 65 JAPAN SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 66 INDIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 67 INDIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 68 INDIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 69 INDIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 INDONESIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 71 INDONESIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 72 INDONESIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 73 INDONESIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 74 PHILIPPINES SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 75 PHILIPPINES SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 76 PHILIPPINES SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 77 PHILIPPINES SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 78 THAILAND SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 79 THAILAND SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 80 THAILAND SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 81 THAILAND SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 VIETNAM SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 83 VIETNAM SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 84 VIETNAM SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 85 VIETNAM SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 86 REST OF ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 87 REST OF ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 88 REST OF ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 89 REST OF ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 90 LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 91 LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 92 LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 93 LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 94 LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 BRAZIL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 96 BRAZIL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 97 BRAZIL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 BRAZIL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 99 ARGENTINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 100 ARGENTINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 101 ARGENTINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 ARGENTINA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 103 REST OF LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 104 REST OF LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 105 REST OF LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 106 REST OF LATIN AMERICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 107 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 108 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 109 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 110 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 111 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 112 UAE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 113 UAE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 114 UAE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 115 UAE SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 116 SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 117 SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 118 SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 SAUDI ARABIA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 120 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 121 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 122 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 124 REST OF MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST, 2021-2030 (USD MILLION)
TABLE 125 REST OF MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES, 2021-2030 (USD MILLION)
TABLE 126 REST OF MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 127 REST OF MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 128 COMPANY REGIONAL FOOTPRINT
TABLE 129 COMPANY INDUSTRY FOOTPRINT
TABLE 130 F. HOFFMANN-LA ROCHE LTD: PRODUCT BENCHMARKING
TABLE 131 F. HOFFMANN-LA ROCHE LTD: WINNING IMPERATIVES
TABLE 132 ABBOTT LABORATORIES: PRODUCT BENCHMARKING
TABLE 133 ABBOTT LABORATORIES: KEY DEVELOPMENTS
TABLE 134 ABBOTT LABORATORIES: WINNING IMPERATIVES
TABLE 135 DANAHER: PRODUCT BENCHMARKING
TABLE 136 DANAHER: WINNING IMPERATIVES
TABLE 137 THERMO FISHER SCIENTIFIC, INC.: PRODUCT BENCHMARKING
TABLE 138 THERMO FISHER SCIENTIFIC, INC.: WINNING IMPERATIVES
TABLE 139 HOLOGIC, INC.: PRODUCT BENCHMARKING
TABLE 140 HOLOGIC, INC.: WINNING IMPERATIVES
TABLE 141 BIOMÉRIEUX: PRODUCT BENCHMARKING
TABLE 142 BECTON, DICKINSON AND COMPANY: PRODUCT BENCHMARKING
TABLE 143 BIO-RAD LABORATORIES, INC.: PRODUCT BENCHMARKING
TABLE 144 DIASORIN S.P.A.: PRODUCT BENCHMARKING
TABLE 145 QUIDELORTHO CORPORATION: PRODUCT BENCHMARKING
TABLE 146 ORASURE TECHNOLOGIES: PRODUCT BENCHMARKING
TABLE 147 SIEMENS: PRODUCT BENCHMARKING
TABLE 148 ILLUMINA, INC.: PRODUCT BENCHMARKING
TABLE 149 SEEGENE INC.: PRODUCT BENCHMARKING
TABLE 150 QIAGEN: PRODUCT BENCHMARKING
TABLE 151 MEDMIRA INC.: PRODUCT BENCHMARKING
TABLE 152 CEPHEID: PRODUCT BENCHMARKING
 
LIST OF FIGURES
FIGURE 1 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET SEGMENTATION
FIGURE 2 RESEARCH TIMELINES
FIGURE 3 DATA TRIANGULATION
FIGURE 4 MARKET RESEARCH FLOW
FIGURE 5 DATA SOURCES
FIGURE 6 SUMMARY
FIGURE 7 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ESTIMATES AND FORECAST (USD MILLION), 2021-2030
FIGURE 8 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSISMARKET VALUE (USD MILLION) AND ESTIMATES AND FORECAST, 2024-2030
FIGURE 9 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
FIGURE 10 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ABSOLUTE MARKET OPPORTUNITY
FIGURE 11 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY REGION
FIGURE 12 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY LOCATION OF TEST
FIGURE 13 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY DEVICES
FIGURE 14 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY TYPE
FIGURE 15 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET ATTRACTIVENESS ANALYSIS, BY END USER
FIGURE 16 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET GEOGRAPHICAL ANALYSIS, 2024-30
FIGURE 17 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST (USD MILLION)
FIGURE 18 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES (USD MILLION)
FIGURE 19 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE (USD MILLION)
FIGURE 20 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER (USD MILLION)
FIGURE 21 FUTURE MARKET OPPORTUNITIES
FIGURE 22 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET OUTLOOK
FIGURE 23 MARKET DRIVERS_IMPACT ANALYSIS
FIGURE 24 RESTRAINTS_IMPACT ANALYSIS
FIGURE 25 KEY TRENDS
FIGURE 26 PORTER’S FIVE FORCES ANALYSIS
FIGURE 27 VALUE CHAIN ANALYSIS
FIGURE 28 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY LOCATION OF TEST
FIGURE 29 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY LOCATION OF TEST
FIGURE 30 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY DEVICES
FIGURE 31 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY DEVICES
FIGURE 32 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY TYPE
FIGURE 33 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY TYPE
FIGURE 34 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY END USER
FIGURE 35 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY END USER
FIGURE 36 GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSIS MARKET, BY GEOGRAPHY, 2021-2030 (USD MILLION)
FIGURE 37 U.S. MARKET SNAPSHOT
FIGURE 38 CANADA MARKET SNAPSHOT
FIGURE 39 MEXICO MARKET SNAPSHOT
FIGURE 40 GERMANY MARKET SNAPSHOT
FIGURE 41 U.K. MARKET SNAPSHOT
FIGURE 42 FRANCE MARKET SNAPSHOT
FIGURE 43 ITALY MARKET SNAPSHOT
FIGURE 44 SPAIN MARKET SNAPSHOT
FIGURE 45 REST OF EUROPE MARKET SNAPSHOT
FIGURE 46 CHINA MARKET SNAPSHOT
FIGURE 47 JAPAN MARKET SNAPSHOT
FIGURE 48 INDIA MARKET SNAPSHOT
FIGURE 49 INDONESIA MARKET SNAPSHOT
FIGURE 50 PHILIPPINES MARKET SNAPSHOT
FIGURE 51 THAILAND MARKET SNAPSHOT
FIGURE 52 VIETNAM MARKET SNAPSHOT
FIGURE 53 REST OF ASIA PACIFIC MARKET SNAPSHOT
FIGURE 54 BRAZIL MARKET SNAPSHOT
FIGURE 55 ARGENTINA MARKET SNAPSHOT
FIGURE 56 REST OF LATIN AMERICA MARKET SNAPSHOT
FIGURE 57 UAE MARKET SNAPSHOT
FIGURE 58 SAUDI ARABIA MARKET SNAPSHOT
FIGURE 59 SOUTH AFRICA MARKET SNAPSHOT
FIGURE 60 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT
FIGURE 61 COMPANY MARKET RANKING ANALYSIS
FIGURE 62 ACE MATRIC
FIGURE 63 F. HOFFMANN-LA ROCHE LTD: COMPANY INSIGHT
FIGURE 64 F. HOFFMANN-LA ROCHE LTD: SEGMENT BREAKDOWN
FIGURE 65 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 66 ABBOTT LABORATORIES: COMPANY INSIGHT
FIGURE 67 ABBOTT LABORATORIES: SEGMENT BREAKDOWN
FIGURE 68 ABBOTT LABORATORIES: SWOT ANALYSIS
FIGURE 69 DANAHER: COMPANY INSIGHT
FIGURE 70 DANAHER: SEGMENT BREAKDOWN
FIGURE 71 DANAHER: SWOT ANALYSIS
FIGURE 72 THERMO FISHER SCIENTIFIC, INC.: COMPANY INSIGHT
FIGURE 73 THERMO FISHER SCIENTIFIC, INC.: SEGMENT BREAKDOWN
FIGURE 74 THERMO FISHER SCIENTIFIC, INC.: SWOT ANALYSIS
FIGURE 75 HOLOGIC, INC.: COMPANY INSIGHT
FIGURE 76 HOLOGIC, INC.: SEGMENT BREAKDOWN
FIGURE 77 HOLOGIC, INC.: SWOT ANALYSIS
FIGURE 78 BIOMÉRIEUX: COMPANY INSIGHT
FIGURE 79 BIOMÉRIEUX: SEGMENT BREAKDOWN
FIGURE 80 BECTON, DICKINSON AND COMPANY: COMPANY INSIGHT
FIGURE 81 BECTON, DICKINSON AND COMPANY: SEGMENT BREAKDOWN
FIGURE 82 BIO-RAD LABORATORIES, INC.: COMPANY INSIGHT
FIGURE 83 BIO-RAD LABORATORIES, INC.: SEGMENT BREAKDOWN
FIGURE 84 DIASORIN S.P.A.: COMPANY INSIGHT
FIGURE 85 DIASORIN S.P.A.: SEGMENT BREAKDOWN
FIGURE 86 QUIDELORTHO CORPORATION: COMPANY INSIGHT
FIGURE 87 QUIDELORTHO CORPORATION: SEGMENT BREAKDOWN
FIGURE 88 ORASURE TECHNOLOGIES: COMPANY INSIGHT
FIGURE 89 ORASURE TECHNOLOGIES: SEGMENT BREAKDOWN
FIGURE 90 SIEMENS: COMPANY INSIGHT
FIGURE 91 SIEMENS: SEGMENT BREAKDOWN
FIGURE 92 ILLUMINA, INC.: COMPANY INSIGHT
FIGURE 93 ILLUMINA, INC.: SEGMENT BREAKDOWN
FIGURE 94 SEEGENE INC.: COMPANY INSIGHT
FIGURE 95 QIAGEN: COMPANY INSIGHT
FIGURE 96 QIAGEN: SEGMENT BREAKDOWN
FIGURE 97 MEDMIRA INC.: COMPANY INSIGHT
FIGURE 98 CEPHEID: COMPANY INSIGHT

Report Research Methodology

Research methodology

Verified Market Research uses the latest researching tools to offer accurate data insights. Our experts deliver the best research reports that have revenue generating recommendations. Analysts carry out extensive research using both top-down and bottom up methods. This helps in exploring the market from different dimensions.

This additionally supports the market researchers in segmenting different segments of the market for analysing them individually.

We appoint data triangulation strategies to explore different areas of the market. This way, we ensure that all our clients get reliable insights associated with the market. Different elements of research methodology appointed by our experts include:

Exploratory data mining

Market is filled with data. All the data is collected in raw format that undergoes a strict filtering system to ensure that only the required data is left behind. The leftover data is properly validated and its authenticity (of source) is checked before using it further. We also collect and mix the data from our previous market research reports.

All the previous reports are stored in our large in-house data repository. Also, the experts gather reliable information from the paid databases.

expert data mining

For understanding the entire market landscape, we need to get details about the past and ongoing trends also. To achieve this, we collect data from different members of the market (distributors and suppliers) along with government websites.

Last piece of the ‘market research’ puzzle is done by going through the data collected from questionnaires, journals and surveys. VMR analysts also give emphasis to different industry dynamics such as market drivers, restraints and monetary trends. As a result, the final set of collected data is a combination of different forms of raw statistics. All of this data is carved into usable information by putting it through authentication procedures and by using best in-class cross-validation techniques.

Data Collection Matrix

PerspectivePrimary ResearchSecondary Research
Supplier side
  • Fabricators
  • Technology purveyors and wholesalers
  • Competitor company’s business reports and newsletters
  • Government publications and websites
  • Independent investigations
  • Economic and demographic specifics
Demand side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customer

Econometrics and data visualization model

data visualiztion model

Our analysts offer market evaluations and forecasts using the industry-first simulation models. They utilize the BI-enabled dashboard to deliver real-time market statistics. With the help of embedded analytics, the clients can get details associated with brand analysis. They can also use the online reporting software to understand the different key performance indicators.

All the research models are customized to the prerequisites shared by the global clients.

The collected data includes market dynamics, technology landscape, application development and pricing trends. All of this is fed to the research model which then churns out the relevant data for market study.

Our market research experts offer both short-term (econometric models) and long-term analysis (technology market model) of the market in the same report. This way, the clients can achieve all their goals along with jumping on the emerging opportunities. Technological advancements, new product launches and money flow of the market is compared in different cases to showcase their impacts over the forecasted period.

Analysts use correlation, regression and time series analysis to deliver reliable business insights. Our experienced team of professionals diffuse the technology landscape, regulatory frameworks, economic outlook and business principles to share the details of external factors on the market under investigation.

Different demographics are analyzed individually to give appropriate details about the market. After this, all the region-wise data is joined together to serve the clients with glo-cal perspective. We ensure that all the data is accurate and all the actionable recommendations can be achieved in record time. We work with our clients in every step of the work, from exploring the market to implementing business plans. We largely focus on the following parameters for forecasting about the market under lens:

  • Market drivers and restraints, along with their current and expected impact
  • Raw material scenario and supply v/s price trends
  • Regulatory scenario and expected developments
  • Current capacity and expected capacity additions up to 2027

We assign different weights to the above parameters. This way, we are empowered to quantify their impact on the market’s momentum. Further, it helps us in delivering the evidence related to market growth rates.

Primary validation

The last step of the report making revolves around forecasting of the market. Exhaustive interviews of the industry experts and decision makers of the esteemed organizations are taken to validate the findings of our experts.

The assumptions that are made to obtain the statistics and data elements are cross-checked by interviewing managers over F2F discussions as well as over phone calls.

primary validation

Different members of the market’s value chain such as suppliers, distributors, vendors and end consumers are also approached to deliver an unbiased market picture. All the interviews are conducted across the globe. There is no language barrier due to our experienced and multi-lingual team of professionals. Interviews have the capability to offer critical insights about the market. Current business scenarios and future market expectations escalate the quality of our five-star rated market research reports. Our highly trained team use the primary research with Key Industry Participants (KIPs) for validating the market forecasts:

  • Established market players
  • Raw data suppliers
  • Network participants such as distributors
  • End consumers

The aims of doing primary research are:

  • Verifying the collected data in terms of accuracy and reliability.
  • To understand the ongoing market trends and to foresee the future market growth patterns.

Industry Analysis Matrix

Qualitative analysisQuantitative analysis
  • Global industry landscape and trends
  • Market momentum and key issues
  • Technology landscape
  • Market’s emerging opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2027
  • Market revenue estimates and forecasts up to 2027, by technology
  • Market revenue estimates and forecasts up to 2027, by application
  • Market revenue estimates and forecasts up to 2027, by type
  • Market revenue estimates and forecasts up to 2027, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

STD Diagnostics Market

report-detail

Download Sample Report

View More Reports